Product Description
Curocell is developing CRC-03 as a treatment for multiple myeloma. (Sourced from: https://curocellbtx.com/en/rnd/#rnd)
Mechanisms of Action: Gene Therapy, CD5, BCMA
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Curocell
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/29/2021 |
News Article |
Fosterville South Announces New Discovery at Golden Mountain and Drilling Results at Lauriston and Beechworth Projects |
|
07/29/2021 |
News Article |
Fosterville South Announces New Discovery at Golden Mountain and Drilling Results at Lauriston and Beechworth Projects |